Annals of Hematology

, Volume 91, Issue 2, pp 203–213

Morphology, cytogenetics, and survival in myelodysplasia with del(20q) or ider(20q): a multicenter study

  • François Mullier
  • Sylvie Daliphard
  • Richard Garand
  • Mélanie Dekeyser
  • Yvan Cornet
  • Isabelle Luquet
  • Pascaline Talmant
  • Steven Richebourg
  • Mauricette Jamar
  • Jean-Michel Dogné
  • Christian Chatelain
  • Lucienne Michaux
  • Bernard Chatelain
Original Article


Isochromosome of the long arm of chromosome 20 with interstitial loss of material [ider(20q)] is a rare cytogenetic abnormality reported in myelodysplastic syndrome (MDS), with neither specific morphological pattern nor clear prognostic significance. The aim of this retrospective multicentric study is to compare the peripheral blood and bone marrow morphology of MDS patients with ider(20q) (n = 13) and del(20q) (n = 21) and controls (n = 47) in order to investigate whether the ider(20q) harbors specific morphological features. The secondary objective is to compare the outcome of patients from both groups. This study performed on the largest cohort of MDS patients with ider(20q) is the first that identifies specific morphological features (hypogranulated and vacuolized neutrophils and neutrophil erythrophagocytosis) allowing the identification of this cytogenetic abnormality with high sensitivity (70%) and specificity (85.7%). Suspected ider(20q) by morphology should therefore support targeted FISH tests in case of non informative karyotype. This combined approach will allow a better estimation of the prevalence of this underdiagnozed entity. The overall survival and progression-free survival did not statistically differ in both groups. However, hypogranulated and vacuolized neutrophils were significantly associated with survival.


ider(20q) del(20q) Myelodysplastic syndrome Morphology Survival 

Supplementary material

277_2011_1286_Fig4_ESM.jpg (23 kb)
Fig. 4

Overall survival in MDS with del(20q) (black) or ider(20q) (grey). 95% confidence interval for the survival curves are showed in thinner lines. The two survival curves did not differ significantly as the logrank showed a chi-square statistic of 0.79 with associated p-value (p) of 0.37. The hazards were not statistically different since the hazard ratio was 0.60 (0.19–1.86) (JPEG 22 kb)

277_2011_1286_MOESM1_ESM.tif (134 kb)
High-resolution image (TIFF 134 kb)


  1. 1.
    Li T, Xue Y, Wu Y, Pan J (2004) Clinical and molecular cytogenetic studies in seven patients with myeloid diseases characterized by i(20q-). Br J Haematol 125(3):337–342PubMedCrossRefGoogle Scholar
  2. 2.
    Douet-Guilbert N, Lai JL, Basinko A, Gueganic N, Andrieux J, Pollet B, Plantier I, Delattre C, Crepin O, Corm S, Le Bris MJ, Morel F, De Braekeleer M (2008) Fluorescence in situ hybridization characterization of ider(20q) in myelodysplastic syndrome. Br J Haematol 143(5):716–720PubMedCrossRefGoogle Scholar
  3. 3.
    Ligon AH, DeAngelo DJ, Atkins L, Dal Cin P (2005) Isochromosome of a deleted 20q may be a relatively common abnormality in myeloid malignancies. Cancer Genet Cytogenet 162(1):89–91PubMedCrossRefGoogle Scholar
  4. 4.
    MacKinnon RN, Campbell LJ (2005) A comparison of two contrasting recurrent isochromosomes 20 found in myelodysplastic syndromes suggests that retention of proximal 20q is a significant factor in myeloid malignancies. Cancer Genet Cytogenet 163(2):176–179PubMedCrossRefGoogle Scholar
  5. 5.
    Saunders K, Czepulkowski B, Sivalingam R, Hayes JP, Aldouri M, Sekhar M, Cummins M, Ho A, Mufti GJ (2005) Isochromosome of a deleted 20q: a rare but recurrent chromosome abnormality in myelodysplastic syndromes. Cancer Genet Cytogenet 156(2):154–157PubMedCrossRefGoogle Scholar
  6. 6.
    Smoley SA, Fink SR, Paternoster SF, Stockero KJ, Nguyen LP, Nguyen PL, Hanson CA, Dewald GW (2007) Frequency, hematopathology, and detection of a new isodicentric variant of deletion 20q. Cancer Genet Cytogenet 173(2):144–149PubMedCrossRefGoogle Scholar
  7. 7.
    Xue Y, Han Y, Li T, Chen S, Zhang J, Pan J, Wu Y, Wang Y, Shen J (2010) Pulmonary alveolar proteinosis as a terminal complication in a case of myelodysplastic syndrome with idic(20q-). Acta Haematologica 123(1):55–58PubMedCrossRefGoogle Scholar
  8. 8.
    Shetty S, Roland B (2008) Isoderivative chromosome 20 in bone marrow: three new cases. Cancer Genet Cytogenet 184(1):72–73PubMedCrossRefGoogle Scholar
  9. 9.
    Lim TH, Lim AS, Tien SL (2006) A novel isoderivative chromosome 20 in a patient with chronic myelomonocytic leukemia. Cancer Genet Cytogenet 170(1):80–82PubMedCrossRefGoogle Scholar
  10. 10.
    Li T, Xue Y, Zhang J, Chen S, Pan J, Wu Y, Wang Y, Shen J (2008) Isodicentric 20q- in two cases of b-cell acute lymphocytic leukemia with the respective t(9;20)(p11;q11.2) and t(9;22)(q34;q11.2). Cancer Genet Cytogenet 181(1):55–59PubMedCrossRefGoogle Scholar
  11. 11.
    Kurtin PJ, Dewald GW, Shields DJ, Hanson CA (1996) Hematologic disorders associated with deletions of chromosome 20q: a clinicopathologic study of 107 patients. Am J Clin Pathol 106(5):680–688PubMedGoogle Scholar
  12. 12.
    Swerdlow S, Campo E, Harris N-L, Jaffe E-S, Pileri S-A, Stein H, Thiele J, Vardiman J-W (2008) Who classification of tumours of haematopoietic and lymphoid tissues. First published, LyonGoogle Scholar
  13. 13.
    Hur M, Lee KM, Cho HC, Park YI, Kim SH, Chang YW, Kim YR, Cho HI (2004) Protein 4.1 deficiency and deletion of chromosome 20q are associated with acquired elliptocytosis in myelodysplastic syndrome. Clin Lab Haematol 26(1):69–72PubMedCrossRefGoogle Scholar
  14. 14.
    Ishida F, Shimodaira S, Kobayashi H, Saito H, Kaku M, Kanzaki A, Yawata Y, Kitano K, Kiyosawa K (1999) Elliptocytosis in myelodysplastic syndrome associated with translocation (1;5)(p10;q10) and deletion of 20q. Cancer Genet Cytogenet 108(2):162–165PubMedCrossRefGoogle Scholar
  15. 15.
    Brezinova J, Zemanova Z, Ransdorfova S, Sindelarova L, Siskova M, Neuwirtova R, Cermak J, Michalova K (2005) Prognostic significance of del(20q) in patients with hematological malignancies. Cancer Genet Cytogenet 160(2):188–192PubMedCrossRefGoogle Scholar
  16. 16.
    Campbell LJ, Garson OM (1994) The prognostic significance of deletion of the long arm of chromosome 20 in myeloid disorders. Leukemia 8(1):67–71PubMedGoogle Scholar
  17. 17.
    Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89(6):2079–2088PubMedGoogle Scholar
  18. 18.
    Liu YC, Ito Y, Hsiao HH, Sashida G, Kodama A, Ohyashiki JH, Ohyashiki K (2006) Risk factor analysis in myelodysplastic syndrome patients with del(20q): prognosis revisited. Cancer Genet Cytogenet 171(1):9–16PubMedCrossRefGoogle Scholar
  19. 19.
    Haase D (2008) Cytogenetic features in myelodysplastic syndromes. Ann Hematol 87(7):515–526PubMedCrossRefGoogle Scholar
  20. 20.
    Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B, Kundgen A, Lubbert M, Kunzmann R, Giagounidis AA, Aul C, Trumper L, Krieger O, Stauder R, Muller TH, Wimazal F, Valent P, Fonatsch C, Steidl C (2007) New insights into the prognostic impact of the karyotype in mds and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 110(13):4385–4395PubMedCrossRefGoogle Scholar
  21. 21.
    Li T, Xue Y, Wu Y, Pan J (2006) Fish studies identify the i(20q-) anomaly as a der(20)del(20)(q11q13)idic(20)(p11). Genes Chromosomes Cancer 45(6):536–539PubMedCrossRefGoogle Scholar
  22. 22.
    Asimakopoulos FA, Green AR (1996) Deletions of chromosome 20q and the pathogenesis of myeloproliferative disorders. Br J Haematol 95(2):219–226PubMedCrossRefGoogle Scholar
  23. 23.
    Wattel E, Lai JL, Hebbar M, Preudhomme C, Grahek D, Morel P, Bauters F, Fenaux P (1993) De novo myelodysplastic syndrome (mds) with deletion of the long arm of chromosome 20: a subtype of mds with distinct hematological and prognostic features? Leuk Res 17(11):921–926PubMedCrossRefGoogle Scholar
  24. 24.
    Valent P, Horny HP (2009) Minimal diagnostic criteria for myelodysplastic syndromes and separation from icus and idus: update and open questions. Eur J Clin Invest 39(7):548–553PubMedCrossRefGoogle Scholar
  25. 25.
    Lesesve JF, Garand R (2009) Evaluation of a telemedicine system for the transmission of morpho/immunological data aiming at the inclusion of patients in a therapeutic trial. Intern J Telemed Appl 2009:767145Google Scholar
  26. 26.
    Shaffer LG, Clovak ML, Campbell LJ (eds) (2009) An International System for Human Cytogenetic Nomenclature (ISCN) (2009). Karger, BaselGoogle Scholar
  27. 27.
    Douet-Guilbert N, Andrieux J, Lai JL, Morice P, Demory JL, Basinko A, Ugo V, Gueganic N, Le Bris MJ, Morel F, De Braekeleer M (2009) Isoderivative of deleted chromosome 20 in primary myelofibrosis (pmf) characterized by molecular cytogenetics and array cgh. Ann Hematol 88(11):1157–1159PubMedCrossRefGoogle Scholar
  28. 28.
    Bain B (2006) Disorders of white cells. In: Blood cells—a practical guide. Blackwell, Oxford, UK, p 398CrossRefGoogle Scholar
  29. 29.
    Mermel CH, McLemore ML, Liu F, Pereira S, Woloszynek J, Lowell CA, Link DC (2006) Src family kinases are important negative regulators of g-csf-dependent granulopoiesis. Blood 108(8):2562–2568PubMedCrossRefGoogle Scholar
  30. 30.
    Ascani S, Sabattini E, Agostinelli C, Piccaluga PP, Zinzani PL, Pileri SA (2004) Erythrophagocytosis by neoplastic cells in a patient with myelodysplastic syndrome. Haematologica 89(4):EIM07PubMedGoogle Scholar
  31. 31.
    Mori H, Tawara M, Yoshida Y, Kuriyama K, Sugahara K, Kamihira S, Tomonaga M (2000) Minimally differentiated acute myeloid leukemia (aml-m0) with extensive erythrophagocytosis and del(20)(q11) chromosome abnormality. Leuk Res 24(1):87–90PubMedCrossRefGoogle Scholar
  32. 32.
    Etzell J, Lu CM, Browne LW, Wang E (2005) Erythrophagocytosis by dysplastic neutrophils in chronic myelomonocytic leukemia and subsequent transformation to acute myeloid leukemia. Am J Hematol 79(4):340–342PubMedCrossRefGoogle Scholar
  33. 33.
    Kuyama J, Fushino M, Take H, Kanayama Y (1995) Myelodysplastic syndrome associated with erythrophagocytosis by blasts and myeloid cells. Int J Hematol 62(4):243–246PubMedCrossRefGoogle Scholar
  34. 34.
    Moretti S, Lanza F, Spisani S, Latorraca A, Rigolin GM, Giuliani AL, Castoldi GL, Traniello S (1994) Neutrophils from patients with myelodysplastic syndromes: relationship between impairment of granular contents, complement receptors, functional activities and disease status. Leuk Lymphoma 13(5–6):471–477PubMedCrossRefGoogle Scholar
  35. 35.
    Ohsaka A, Saionji K, Igari J, Watanabe N, Iwabuchi K, Nagaoka I (1997) Altered surface expression of effector cell molecules on neutrophils in myelodysplastic syndromes. Br J Haematol 98(1):108–113PubMedCrossRefGoogle Scholar
  36. 36.
    An X, Mohandas N (2008) Disorders of red cell membrane. Br J Haematol 141(3):367–375PubMedGoogle Scholar
  37. 37.
    Douet-Guilbert N, Basinko A, Morel F, Le Bris MJ, Ugo V, Morice P, Berthou C, De Braekeleer M (2008) Chromosome 20 deletions in myelodysplastic syndromes and philadelphia-chromosome-negative myeloproliferative disorders: characterization by molecular cytogenetics of commonly deleted and retained regions. Ann Hematol 87(7):537–544PubMedCrossRefGoogle Scholar
  38. 38.
    Soupir CP, Vergilio JA, Kelly E, Dal Cin P, Kuter D, Hasserjian RP (2009) Identification of del(20q) in a subset of patients diagnosed with idiopathic thrombocytopenic purpura. Br J Haematol 144(5):800–802PubMedCrossRefGoogle Scholar
  39. 39.
    Voulgarelis M, Giannouli S, Ritis K, Tzioufas AG (2004) Myelodysplasia-associated autoimmunity: clinical and pathophysiologic concepts. Eur J Clin Invest 34(10):690–700PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • François Mullier
    • 1
    • 2
  • Sylvie Daliphard
    • 3
  • Richard Garand
    • 4
  • Mélanie Dekeyser
    • 1
  • Yvan Cornet
    • 1
  • Isabelle Luquet
    • 5
  • Pascaline Talmant
    • 6
  • Steven Richebourg
    • 6
  • Mauricette Jamar
    • 7
  • Jean-Michel Dogné
    • 2
  • Christian Chatelain
    • 8
  • Lucienne Michaux
    • 9
  • Bernard Chatelain
    • 1
  1. 1.Laboratory of Hematology, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for LIfe Sciences (NARILIS), UCL Mont-GodinneYvoirBelgium
  2. 2.Department of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for LIfe Sciences (NARILIS), FUNDPUniversity of NamurNamurBelgium
  3. 3.Laboratory of HematologyCHU Robert DebréReimsFrance
  4. 4.Laboratory of HematologyCHU NantesNantesFrance
  5. 5.Laboratory of Hematology and Cytogenetics, Hôpital Robert DebréCHU ReimsReimsFrance
  6. 6.Unit of Hematological CytogeneticsCHU NantesNantesFrance
  7. 7.Laboratory of Cytogenetics, Human Genetic DepartmentCHU LiègeLiègeBelgium
  8. 8.Clinical HematologyNamur Thrombosis and Hemostasis Center (NTHC), UCL Mont-GodinneMont-GodinneBelgium
  9. 9.Center for Human GeneticsKULeuvenLeuvenBelgium

Personalised recommendations